Screener
CME Group CME Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 65.1%-0.2pp | 65.6%+0.6pp | 64.9%+0.7pp | 65%+1.3pp | 65.3%+2.5pp | |
| Net margin | 63.9%+5.4pp | 63.6%+5.9pp | 62.5%+4.9pp | 58.8%+1.5pp | 58.4%+1.5pp | |
| Returns | ||||||
| Return on equity | 15.9%+2.3pp | 16%+2.6pp | 14.8%+1.5pp | 13.3%+1.0pp | 13.6%+1.7pp | |
| Return on invested capital | 15.3%+1.1pp | 15.4%+1.6pp | 15.2%+1.0pp | 14%+1.1pp | 14.2%+2.0pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 1×0.0× | 1×0.0× | 1×0.0× | 1×0.0× | 1×0.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | 0.4×0.0× | 0.3×-0.3× | -0.2×-0.4× | 0.3×-0.1× | 0.4×-0.1× | |
| Per Share | ||||||
| Book value per share | $73.41-4.6% | $73.29-2.3% | $79.73+8.4% | $78.21-0.2% | $76.98+0.2% | |
| Valuation | ||||||
| Market capitalization | $96.29B-6.9% | $107.16B+12.1% | $98.47B+17.7% | $97.37B+22.5% | $97.79B+38.1% | |
| Price / earnings | 22.3×-5.2× | 24.9×-1.4× | 24.2×+0.4× | 25.9×+2.9× | 26×+4.5× | |
| Price / sales | 14.2×-1.8× | 15.9×+0.6× | 15.1×+1.5× | 15.2×+2.1× | 15.2×+3.0× | |
| Price / book | 3.6×-0.1× | 4×+0.5× | 3.4×+0.3× | 3.5×+0.6× | 3.5×+1.0× | |
| EV / EBITDA | 21.2×-3.2× | 23.6×+0.2× | 22.6×+1.6× | 23.1×+2.7× | 23.1×+3.7× | |
| Dividend yield | 4.2%+0.5pp | 3.8%-0.2pp | 4%-0.3pp | 4%-0.5pp | 3.9%-1.1pp |
FAQ
- Where do CME Group's ratios come from?
- Every ratio is computed from CME Group's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
